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Background: Chronic Stenotrophomonas maltophilia infection is a risk factor for pulmonary exacerbation in cystic fibrosis (CF) but its impact on
subsequent clinical outcomes is unknown. The aim of this study was to determine the effect of chronic S. maltophilia infection and associated
antimicrobial therapy on the recovery of forced expiratory lung volume in 1 s (FEV1) following pulmonary exacerbation.
Methods: This was a retrospective cohort study of patients with CF followed at The Hospital for Sick Children and St. Michael's Hospital from
1997 to 2008. The primary outcome was the difference in FEV1 percent predicted from baseline to follow up after a pulmonary exacerbation.
Secondary outcomes for the effect of antimicrobial therapy included time to subsequent exacerbation.
Results: There were 1667 pulmonary exacerbations in 440 CF patients. Patients with chronic S. maltophilia infection did not recover their baseline
FEV1 following 31% of exacerbations and had an overall mean FEV1 decline of 1.84% predicted after exacerbation. Older (p=0.02), female
(p=0.02) patients with lower BMI z score (p=0.002) and Burkholderia cepacia complex infection (p=0.005), but not chronic S. maltophilia
infection (p=0.86), had a greater decrease in follow up FEV1% pred compared to baseline. The number of days of antibiotic therapy against S.
maltophilia during a pulmonary exacerbation was not associated with a significant difference in the FEV1 recovery (p=0.69) or with a longer time
to subsequent pulmonary exacerbation (p=0.56).
Conclusions: Although CF patients experience a significant decline in lung function following exacerbation, chronic S. maltophilia infection and
associated antimicrobial therapy do not affect subsequent lung function recovery.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Stenotrophomonas maltophilia; Pulmonary exacerbationAbbreviations: ABPA, allergic bronchopulmonary aspergillosis; BMI, body mass index; CF, cystic fibrosis; FEV1, forced expiratory volume in 1 s; MRSA,
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Chronic Stenotrophomonas maltophilia infection in cystic
fibrosis (CF) patients has recently been shown to be an
independent risk factor for pulmonary exacerbation [1].
Antibiotic use, however, is a known risk factor for the isolation
of S. maltophilia in the respiratory tract of CF patients and
increased treatment of pulmonary exacerbations may simply be
selecting out S. maltophilia in the airways of sicker CF patients
[2–5]. The consequences of the increased number of pulmonary
exacerbations in CF patients with chronic S. maltophilia
infection are unknown.
Using the CF Foundation Patient Registry, Goss and col-
leagues have shown that a quarter of CF patients do not recover
their baseline pulmonary function following an exacerbation
and have identified risk factors associated with failure to re-
cover baseline lung function [6]. We hypothesized that chronic
S. maltophilia infection is associated with poorer outcome
during pulmonary exacerbations in CF patients and that out-
come may be influenced by whether or not specific antimicro-
bial therapy against S. maltophilia was initiated. The aim of
this study was to determine the impact of chronic S. maltophilia
infection on the recovery of forced expiratory lung volume in
1 s (FEV1) following pulmonary exacerbation and the role of
anti-S. maltophilia antimicrobial therapy on FEV1 recovery.
2. Materials and methods
2.1. Study design and definitions
This was a retrospective cohort study using the Toronto CF
Database of patients with CF followed at The Hospital for Sick
Children and St. Michael's Hospital (Toronto, Canada) from
1997 to 2008. Patients were included in the study if they had a
confirmed diagnosis of CF based on the following: a) the
presence of clinical features consistent with CF, or b) a positive
family history for CF plus either 2 documented sweat chloride
valuesN60 mEq/L measured by quantitative pilocarpine ionto-
phoresis test, genetic testing showing 2 CF-causing mutations
or a nasal potential difference consistent with CF [7]. Patients
were excluded once they had received a lung transplant.
As previously, a pulmonary exacerbation was defined as a
hospitalization for respiratory symptoms requiring antibiotics
[1]. Each pulmonary exacerbation was classified into one of
three groups based on previous definitions [1]: 1) chronic
S. maltophilia: 2 or more positive sputum or bronchoalveolar
cultures for S. maltophilia in previous 12 months, 2) inter-
mittent S. maltophilia: 1 positive sputum or bronchoalveolar
cultures for S. maltophilia in previous 12 months or a previous
positive culture, and 3) never S. maltophilia: never having a
positive sputum or bronchoalveolar culture for S. maltophilia.
For baseline characteristics, patients were classified into one of
these three groups based on respiratory tract culture results from
the 12 months prior to the first year of observation.
The primary outcome was the difference in FEV1 percent
predicted from baseline to follow up after a pulmonary exac-
erbation in each of these three groups. Baseline FEV1 wasdefined as the best FEV1 in the 6 months before the hos-
pitalization date for pulmonary exacerbation. Follow up FEV1
was defined as the best FEV1 in the 3 months following the
hospitalization date for pulmonary exacerbation [6]. Hospital-
ization FEV1 was defined as the worst FEV1 7 days prior
or 4 days after the date of hospital admission for pulmonary
exacerbation [8]. FEV1 recovery was defined as a follow up
FEV1 greater than or equal to 90% of the baseline FEV1 [6].
Consecutive pulmonary exacerbations within 3 weeks of
antibiotic treatment were considered as a single event.
Antibiotic therapy for S. maltophilia was defined as the
use of antibiotics with activity against S. maltophilia, such
as trimethoprim–sulfamethoxazole, levofloxacin, ticarcillin–
clavulanate and doxycycline [9,10], in the 14 days before or
21 days after the date of hospital admission for pulmonary
exacerbation.
This study was approved by the Research Ethics Board at
The Hospital for Sick Children (1000013759) and St. Michael's
Hospital (09-087c).2.2. Statistical analysis
Analysis of variance (ANOVA) was used to compare con-
tinuous variables at baseline and chi-square independent test was
used to assess the association to the three levels of S. maltophilia
groups. A generalized linear mixed model (with appropriate
covariance structures of power to account for the longitudinal
nature of repeated data structure of FEV1% of each subject)
was generated to analyze the relationship between chronic
S. maltophilia infection and change in FEV1% predicted ac-
counting for age, gender, BMI z score, pancreatic insufficiency,
Pseudomonas aeruginosa, Burkholderia cepacia complex or
methicillin-resistant Staphylococcus aureus (MRSA) infection,
allergic bronchopulmonary aspergillosis (ABPA) (as defined by
the treating physician in combination with increased IgE levels),
drop in FEV1% predicted from baseline to exacerbation, time
since baseline FEV1 measurement, and use of antibiotic therapy
specific for S. maltophilia, based on risk factors identified in
previous studies [6,11]. Medicaid insurance was not included
due to the existence of universal healthcare insurance in Canada.
A second model, adjusting for significant variables identified
in the first model, was generated to analyze the relationship
between days of S. maltophilia antibiotic therapy during pul-
monary exacerbation and change in FEV1% predicted and time
to subsequent pulmonary exacerbation.2.3. Power analysis
This study had 80% power, at the 5% level of significance,
to detect a minimum difference of 1.4% predicted in FEV1
recovery between the never and chronic S. maltophilia groups.
Linear regression power analysis demonstrated that, this study
had greater than 87% power to detect a minimum difference in
the slope of 0.1 for FEV1% predicted (SD 8.30) and 80% power
to detect a minimum difference in the slope for time to sub-
sequent exacerbation (days) of 4.0 (standard deviation of up
Fig. 1. Box plot of difference in forced expiratory volume in 1 s (FEV1) percent
predicted from baseline to follow up after pulmonary exacerbation in patients with
chronic S.maltophilia infection (Chronic S.maltophilia), intermittent S.maltophilia
infection (Intermittent S. maltophilia) and in those who never had S. maltophilia
infection (Never S. maltophilia).
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(SD 12.68).
3. Results
3.1. Baseline patient characteristics
From 1997 to 2008, of the 881 CF patients followed in the
Toronto CF Database, 440 patients had at least one pulmonary
exacerbation requiring hospitalization and antibiotics. Of
these 440 patients, 23 (5%) patients had chronic S. maltophilia
infection, 29 (7%) had intermittent S. maltophilia infection
and 388 (88%) had never had S. maltophilia isolated from the
respiratory tract. Baseline patient characteristics are summa-
rized by S. maltophilia infection status in Table 1, demonstrat-
ing no significant differences. Of note, patients in each of the
three groups had a similar average number of respiratory
cultures taken per year (chronic 2.9, intermittent 3.4 and never
3.0 cultures/yr p=0.49).
3.2. FEV1 recovery following pulmonary exacerbation
During the study period, there were 1667 pulmonary exac-
erbations identified that required hospitalization and antibiotics. Of
these, 366 (22%) were in patients with chronic S. maltophilia in-
fection, 184 (11%)were in patients with intermittent S. maltophilia
infection and 1117 (67%) were in patients who never had
S. maltophilia. The adjusted difference in FEV1% predicted from
baseline to follow up after exacerbation is represented, according
to S. maltophilia infection status, in Fig. 1. Patients with chronic
S. maltophilia infection had amean difference in FEV1%predicted
from baseline to follow up of −1.84% pred (SE 1.49), patients
with intermittent S. maltophilia infection had a difference of
−1.86% pred (SE 1.53) and patients who never had S. maltophilia
had a difference of −2.25% pred (SE 1.40).
The effect of chronic S. maltophilia infection on the dif-
ference in FEV1% predicted from baseline to follow up after
each exacerbation was evaluated using a linear regression
model, adjusting for the previous identified variables. In this
model, older (p=0.02), female (p=0.02) patients with lower
BMI z score (p=0.002) and B. cepacia complex infection
(p=0.005), had a greater decrease in follow up FEV1% pred
compared to baseline (Table 2). Patients who had a greater FEV1Table 1
Baseline characteristics of patients with pulmonary exacerbations.
Chronic S. maltophilia (n=23) Interm
No. resp cultures/yr, mean (IQR) 2.9 (1–4) 3.4 (1
Age in years, mean (IQR) 19.8 (11.7–26.9) 18.6 (
Sex (male) 52.2% 58.6%
Pancreatic insufficient 91.3% 89.7%
CFRD 4.3% 17.2%
Mean BMI z score (IQR) −0.5 (−1.3 to 0.1) −0.8
Mean baseline FEV1% pred (IQR) 56.3 (42.5–67.3) 62.8 (
P. aeruginosa positive 40.9% 57.7%
B. cepacia positive 4.5% 15.4%
IQR: interquartile range.drop from baseline to the time of exacerbation also had lower
FEV1 in follow up after exacerbation (pb0.0001). Of note,
patients with ABPA had a greater FEV1 in follow up after
exacerbation (p=0.0008). Patients with chronic S. maltophilia
infection (p=0.86) or who had S. maltophilia antibiotic therapy
(p=0.53) did not have a significant difference in FEV1% pred
recovery following exacerbation. Using previous definitions
to dichotomize FEV1 recovery [6], our data showed that FEV1
was not recovered after 31% of exacerbations with chronic
S. maltophilia infection, 23% of exacerbations with intermittent
S. maltophilia infection and 31% of exacerbations with no
S. maltophilia infection. Lower BMI z score, B. cepacia com-
plex infection and greater FEV1 drop were identified as sig-
nificant risk factors for failing to recover FEV1 in a generalized
mixed model.
3.3. Effect of S. maltophilia antibiotic therapy on FEV1
recovery and time to subsequent pulmonary exacerbation
To examine the effect of antibiotic therapy directed against
S. maltophilia on FEV1 recovery after a pulmonary exacerbation,
a linear regression model was generated only for patients with
S. maltophilia infection (chronic and intermittent S. maltophilia
infections). Of the 366 exacerbations with chronic S. maltophiliaittent S. maltophilia (n=29) Never S. maltophilia (n=388) p value
–4) 3.0 (2–4) 0.49
12.3–21.9) 20.0 (10.0–27.4) 0.85
50.1% 0.67
86.6% 0.91
13.7% 0.36
(−1.5 to 0.1) −0.7 (−1.3 to 0.1) 0.77
47.4–73.8) 62.2 (45.3–77.1) 0.52
61.6% 0.05
18.1% 0.20
Table 2
Adjusted model results of FEV1% predicted recovery following pulmonary
exacerbation.
Variable Regression estimate SE p value
Increasing age −0.06 0.02 0.02
Gender (female) −1.11 0.49 0.02
P. aeruginosa −1.23 0.82 0.13
B. cepacia complex −1.64 0.58 0.005
Lower BMI z score −0.65 0.21 0.002
Allergic bronchopulmonary
aspergillosis (ABPA)
3.16 0.94 0.0008
Greater FEV1 drop from
baseline to exacerbation
−0.40 0.02 b0.0001
Chronic S. maltophilia 0.03 0.59 0.86
S. maltophilia antibiotic treatment −0.008 0.01 0.53
11V. Waters et al. / Journal of Cystic Fibrosis 11 (2011) 8–13infection, 121 (33%) of them were treated with S. maltophilia
antibiotic therapy which eliminated S. maltophilia for at least
1 year in only 31 (26%) of these exacerbations. Of the 184
exacerbations with intermittent S. maltophilia infection, 26 (14%)
of them were treated with S. maltophilia antibiotic therapy
which eliminated S. maltophilia for at least 1 year in 15 (58%)
of these exacerbations. Fig. 2 illustrates the number of days of
S. maltophilia antibiotic therapy received for every exacerbation
(mean 20 days;median 14 days; range 1–134 days). Themajority
of these exacerbations (95%) were treated with only one
S. maltophilia antimicrobial agent and in most cases (76%),
S. maltophilia antimicrobial treatment was initiated on the day of
hospitalization.
The difference in FEV1% predicted from baseline to follow
up after pulmonary exacerbations with chronic or intermittent
S. maltophilia infection was evaluated adjusting for significant
variables from the previous model. In this adjusted model,
patients with a greater FEV1 drop from baseline to the time of
exacerbation (pb0.0001) had a greater decrease in follow up
FEV1 and patients with ABPA had a greater FEV1 in follow up
after exacerbation (p=0.03). The number of days of antibiotic
therapy against S. maltophilia during a pulmonary exacerbation
was not associated with a significant difference in the FEV1Fig. 2. Histogram of total number of days of S. maltophilia antibiotic therapy
received per episode of pulmonary exacerbation in patients treated with
S. maltophilia antibiotic therapy.recovery following a pulmonary exacerbation (p=0.69). The
results were similar when the gain in FEV1% predicted from
hospitalization to follow up after pulmonary exacerbation was
evaluated.
For patients with chronic and intermittent S. maltophilia
infections, the time to subsequent pulmonary exacerbation was
then determined. The estimate of the time to subsequent pul-
monary exacerbation was 574.85 days (SE 113.45). A linear
regression model was then generated to examine the relationship
between time to subsequent exacerbation and number of days of
antibiotic therapy against S. maltophilia during the exacerbation,
adjusting for the previously identified variables. Lower BMI z
score (p=0.04) was significantly associated with a shorter time
to subsequent pulmonary exacerbation. Antibiotic treatment
against S. maltophilia during a pulmonary exacerbation was
not associated with a longer time to subsequent pulmonary
exacerbation (p=0.56). When S. maltophilia antibiotic therapy
was dichotomized into ≥14 days or b14 days of antibiotic
therapy [12], the same variables were significant in evaluating
FEV1 and time to subsequent pulmonary exacerbation.
4. Discussion
We have previously shown that chronic S. maltophilia
infection in CF patients is an independent risk factor for
pulmonary exacerbation requiring hospitalization and antibiotic
therapy and this study confirms that there are more pulmonary
exacerbations per patient with chronic S. maltophilia infection
[1]. This study showed that chronic S. maltophilia status does
not affect FEV1 recovery and S. maltophilia antibiotic treatment
does not influence the recovery of, or the gain in, FEV1 during a
pulmonary exacerbation or the time to subsequent pulmonary
exacerbation, regardless of the length of therapy.
Recurrent pulmonary exacerbations are associated with
significant increases in morbidity and mortality in CF [11,13–
16]. Similar to a previous study by Sanders et al., there was a
failure to recover baseline FEV1 in approximately 30% of
exacerbations in our study [6]. As a population whole, patients
had an approximately 2% predicted decrease in follow up FEV1
compared to baseline; other studies have noted an approximately
3% decrease in FEV1 following pulmonary exacerbations [8].
Adjusting for similar variables as previous analyses [6], this
study noted that older age, female gender, lower BMI,B. cepacia
complex infection, and a larger drop in FEV1 at the time of
exacerbation, negatively affected lung function recovery after a
pulmonary exacerbation. In contrast, patients with ABPA had
improved lung function following pulmonary exacerbation,
likely reflecting the effect of steroid therapy which was
administered to the majority (59%) of them [17]. Although
persistent P. aeruginosa, B. cepacia complex and MRSA were
risk factors for worse lung function following exacerbation in
the Sanders study, chronic S. maltophilia infection was not a risk
factor in our study. Thus, while CF patients chronically infected
with S. maltophilia have more pulmonary exacerbations [1], it
does not appear as though they do worse, in terms of lung
function, following a pulmonary exacerbation than patients who
have intermittent or who never had S. maltophilia. This is in
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over time is not greater in chronic S. maltophilia infected
patients [1]. It is still not clear, however, how chronic
S. maltophilia is associated with more exacerbations and more
exacerbations are associated with greater FEV1 decline [18] but
chronic S. maltophilia infection is not associated with greater
FEV1 decline. Exactly how pulmonary exacerbations contribute
to the rate of FEV1 decline has yet to be determined.
Although the primary aim of this study was to examine the
effect of chronic S. maltophilia infection on lung function
recovery following pulmonary exacerbations, the inclusion of
detailed information regarding antibiotic therapy permitted us to
investigate, albeit in a limited retrospective manner, its effect on
clinical outcomes. The goal of antibiotic treatment during a
CF pulmonary exacerbation is to decrease the bacterial load
in the airways (possibly eliminating the bacteria) and decrease
the associated inflammation thereby improving lung function
and prolonging the time to subsequent exacerbation [19,20].
Antibiotic therapy targeting S. maltophilia during pulmonary
exacerbations did not affect the degree of FEV1 recovery
following the exacerbation or the time to subsequent exacer-
bation despite the fact that the median number of days of
antibiotic therapy was 14 days, which is standard of care for
the treatment of pulmonary exacerbations [12]. It is important
to note, however, that there was a wide variation in the number
of days of antibiotic therapy. In addition, almost all patients
were treated with only one antimicrobial drug targeting
S. maltophilia, resulting in elimination of S. maltophilia from
the airways in only one quarter of chronic S. maltophilia
pulmonary exacerbations. This raises the question of whether
the antimicrobial treatment of S. maltophilia in these patients
was truly effective. S. maltophilia is notorious for its intrinsic
resistance to a broad spectrum of antimicrobial agents and it is
often recommended to treat S. maltophilia infections with two
antibiotics with different mechanisms of action [9]. In the
analysis of the effect of antimicrobial therapy on clinical
outcomes, patients with intermittent infection were included
with patients with chronic infection due to the small sample
size. It is possible that chronically infected patients may benefit
more from antimicrobial therapy during exacerbations. Alter-
natively, it has been suggested that it is the occurrence of the
pulmonary exacerbation itself, as evidenced by the initial drop
in FEV1 at the time of exacerbation, rather than any of the
antimicrobial therapy we administer during an exacerbation,
which is the most important determinant of long-term outcome.
Other large epidemiologic studies have demonstrated that the
duration of antibiotic treatment during pulmonary exacerbations
does not affect the lung function decline seen after pulmonary
exacerbations in CF patients [8,12]. Prospective interventional
studies with measurements of sputum bacterial density are
needed to definitively address the role of S. maltophilia anti-
microbial therapy during exacerbations.
This study has several limitations. The definition of chronic
infection was based on previous work which identified a
specific serologic response to S. maltophilia in this group of
patients [1]. It does not take into account, however, the number
of respiratory cultures done per year. It is possible that sickerpatients have more respiratory cultures taken, have more
S. maltophilia detected as a result and chronic S. maltophilia
status thus simply reflects a sicker patient population. Chronic
definitions based on the percentage of positive cultures may
therefore also be appropriate. However, the average number of
respiratory cultures taken per year was similar in our three study
groups. In addition, we did not do molecular typing on the
S. maltophilia isolates as the isolates were not available due to
the retrospective nature of the study. This limits our ability to
state that these patients were truly chronically infected with the
same clone of S. maltophilia over time. The study also had a
limited number of patients with chronic S. maltophilia infection
which may affect its power to identify risk factors for failing to
recover FEV1 [6]. However, the study was adequately powered
to detect a minimum difference of 1.4% predicted in FEV1
recovery between patients with chronic versus no S. maltophilia
and for the effect of S. maltophilia antibiotic therapy, a
difference of 0.1 in the slope for FEV1% predicted and of 4 days
in the slope for time to subsequent exacerbation, all clinically
relevant minimum differences. In addition, this study analyzed
repeated exacerbations which are not independent events and
hence a generalized linear mixed model with an appropriate
covariance structure was used to account for the longitudinal
nature of the repeated data. Finally, antimicrobial susceptibility
data for infecting S. maltophilia strains was not collected; it
is possible that these strains were resistant to the antibiotics
chosen to treat S. maltophilia during the exacerbation. How-
ever, the authors presume that antibiotics were chosen based on
the most recent culture results and the role of sensitivity testing
in chronic airway infection is being debated.
In conclusion, a significant proportion of CF patients do not
recover their lung function following pulmonary exacerbation,
particularly older, undernourished female patients infected with
B. cepacia complex. CF patients with chronic S. maltophilia
infection, however, are not at increased risk of lung decline
after an exacerbation. In addition, currently used antimicrobial
therapies directed at S. maltophilia during a pulmonary exacer-
bation do not appear to affect lung function recovery or time to
subsequent exacerbation. Future clinical trials may be required
to identify more effective therapies to prevent the increased rate
of hospitalization seen in CF patients chronically infected with
S. maltophilia.
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